Loading…
World's largest maker of store-brand over-the-counter health and infant-formula products for retailers.
World's largest maker of store-brand over-the-counter health and infant-formula products for retailers.
Splits between store-brand products it makes for retailers' own labels in the US, where it competes on price and supply reliability, and its own branded consumer-health lines in Europe, built through the 2015 Omega Pharma purchase. It sold its generic prescription-drug business in 2021 and later added Opill, a non-prescription contraceptive pill, through its HRA Pharma purchase.
Moat: narrow (scale, cost advantage, regulatory licence). Scale manufacturing and FDA-registered facilities are costly barriers for smaller store-brand suppliers.
Headquarters: Dublin, Ireland · Founded: 1887 · Employees: 8,100
Size Perrigo (PRGO) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $2.20B, the 1729th largest of 3,117 United States companies the cockpit tracks. Shares closed at $15.85 on 6 Nov 2026.
Performance Over six months the shares gained 35.4%, against -13.4% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.
Growth Revenue fell 4.5% over the last twelve months (peer median +0.4%); the operating margin is 4.6% (peer median 11.5%).
Valuation It trades at 6.3× forward earnings against a peer median of 17.2× (cheapest of 15).
Price implies For today's price to make sense, revenue must grow about 13% a year for seven years (Req g). Recent delivered growth is +1%, so the hurdle is +12 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.9 points below its cost of capital (6.6% WACC).
Credit Perrigo has 3 bonds outstanding ($1.77B), rated B+ by the agencies and trading like BB at a weighted spread of 189 bp.
Short interest Short interest is 17.4% of the free float (15 Oct 2026).
Next results Next results expected around 1 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $4.09B | $4.25B | $4.37B | $4.66B | $4.45B |
| Revenue growth | — | -3% | -6% | +5% | — |
| Gross profit | $1.67B | $1.50B | $1.54B | $1.68B | $1.46B |
| EBITDA | $533M | $682M | $644M | $642M | $512M |
| Net income | -$1.77B | -$1.43B | -$172M | -$12.7M | -$141M |
| Free cash flow | $168M | $145M | $245M | $304M | $211M |
| Capital expenditure | $72.4M | $94.9M | $132M | $102M | $96.4M |
| Total debt | $3.29B | $3.82B | $3.80B | $4.26B | $4.32B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Perrigo PRGO | $2.20B | +35% | -4% | 5% | 6.3× | 13.1% |
| Kenvue KVUE | n/a | +12% | n/a | n/a | n/a | n/a |
| Reckitt Benckiser RKT.L | $47.6B | +22% | -2% | 28% | 16.4× | 1.6% |
| Church & Dwight CHD | $25.8B | +17% | +2% | 18% | 27.4× | 6.9% |
| Haleon HLN.L | $40.1B | +1% | +1% | 23% | 16.3× | 4.6% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | PRGO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +9.3% | -0.6% | 6th highest of 21 |
| 6-month return | +35.4% | -13.4% | 3rd highest of 21 |
| Distance from 52-week high | -5.7% | -27.1% | 2nd highest of 21 |
| Revenue growth (TTM) | -4.5% | +0.4% | 7th lowest of 20 |
| Operating margin | 4.6% | 11.5% | 5th lowest of 19 |
| Forward P/E | 6.3× | 17.2× | cheapest of 15 |
| Growth the price implies (Req g, 7 yrs) | 13.1% | 1.2% | 3rd most demanding of 16 |
| Growth delivered (Del g) | +0.8% | +6.4% | 5th lowest of 16 |
| Hurdle (Req g minus delivered) | +12.3 pp | -7.6 pp | 3rd most demanding of 16 |
| ROIC minus cost of capital | -3.9 pp | +1.6 pp | 4th lowest of 18 |
| EV / EBITDA | 9.8× | 10.5× | 3rd cheapest of 5 |
| Net debt / EBITDA | 5.4× | 2.2× | 2nd most indebted of 5 |
| Bond spread | 189 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Perrigo PRGO | United States | $2.20B | +35% | -4% | 5% | 6.3× | 13.1% | +0.8% |
| Biohaven BHVN | United States | $2.19B | +47% | n/a | n/a | n/a | n/a | n/a |
| Haw Par H02.SI | Singapore | $2.18B | -27% | -13% | 30% | 12.4× | 3.7% | +15.7% |
| Nanjing King-friend Biochemical Pharmaceutical 603707.SS | China | $2.15B | -3% | +9% | 14% | 22.8× | 6.1% | +6.4% |
| NewAmsterdam Pharma NAMS | United States | $2.26B | -51% | -26% | -900% | n/a | n/a | n/a |
| Fujian Cosunter Pharmaceutical 300436.SZ | China | $2.26B | -35% | 0% | -47% | n/a | n/a | n/a |
| CSPC Hunan Jingfeng Pharmaceutical 000908.SZ | China | $2.13B | -27% | +5% | -18% | n/a | n/a | n/a |
| Tonghua Golden-Horse Pharmaceutical Industry 000766.SZ | China | $2.12B | -41% | -18% | 9% | n/a | 37.9% | +0.9% |
| Zhejiang Jiuzhou Pharmaceutical 603456.SS | China | $2.12B | +17% | -1% | 14% | 17.5× | 2.4% | +15.7% |
| Dermapharm DMP.DE | Germany | $2.11B | -25% | 0% | 22% | 14.5× | -3.8% | +8.0% |
| Tonghua Dongbao Pharmaceutical 600867.SS | China | $2.29B | -14% | +18% | n/a | 26.2× | 1.6% | +0.3% |
| Zymeworks ZYME | United States | $2.10B | +24% | -70% | -419% | 12.0× | n/a | n/a |
| InnoCare Pharma 9969.HK | Hong Kong | $2.31B | -13% | +146% | 35% | 37.0× | 0.8% | +341.1% |
| Harbin Pharmaceutical 600664.SS | China | $2.10B | +55% | +2% | 5% | 23.1× | -2.9% | +8.2% |
| Shandong Buchang Pharmaceuticals 603858.SS | China | $2.31B | -7% | +4% | 10% | n/a | -2.2% | -5.8% |
| Zhejiang Hisun Pharmaceutical 600267.SS | China | $2.32B | +18% | -7% | 15% | 17.0× | -9.1% | -1.5% |
| Jinyu Bio-Technology 600201.SS | China | $2.04B | -15% | +22% | 10% | 62.4× | 24.4% | -2.4% |
| Prestige Consumer Healthcare PBH | United States | $2.04B | -18% | -1% | 26% | 9.3× | -0.2% | +2.9% |
| Henan Lingrui Pharmaceutial 600285.SS | China | $2.02B | +7% | +5% | 22% | 15.9× | -4.8% | +10.6% |
| Qingdao Baheal Medical 301015.SZ | China | $2.02B | +4% | -6% | 8% | 23.5× | 11.9% | +5.0% |
| Grand Pharmaceutical 0512.HK | Hong Kong | $2.01B | -27% | +7% | 13% | 9.8× | 1.2% | +14.1% |
Perrigo has 3 bonds outstanding with $1.77B face value. The agencies rate it B+; its bonds trade like BB. Weighted yield 6.63%, a spread of 189 bp over government bonds.